3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
7
Triple Negative Breast Neoplasms
5
Neoplasms
4
Ovarian Neoplasms
3
Pancreatic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Zollinger-Ellison Syndrome
1
Vipoma
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pheochromocytoma
1
Pathologic Complete Response
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Liver Neoplasms
1
Insulinoma
1
Hemangiosarcoma
1
Glucagonoma
1
Gliosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
veliparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled